As of June 16, 2025, Imagion Biosystems Ltd (IBX.AX) reports a ROE (Return on Equity) of 90.54%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Imagion Biosystems Ltd's ROE (Return on Equity)
Over recent years, Imagion Biosystems Ltd's ROE (Return on Equity) has shown a stable trend. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2024-12-31 | 90.54% |
| 2023-12-31 | 329.30% |
| 2022-12-31 | -209.67% |
| 2021-12-31 | -45.28% |
| 2020-12-31 | -41.54% |
This slight downward trend highlights how Imagion Biosystems Ltd manages its efficiency in generating profits from shareholders' equity over time.
Comparing Imagion Biosystems Ltd's ROE (Return on Equity) to Peers
To better understand Imagion Biosystems Ltd's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Imagion Biosystems Ltd (IBX.AX) | 90.54% |
| Analytica Ltd (ALT.AX) | 1525.83% |
| Allegra Medical Technologies Ltd (AMT.AX) | 243.33% |
| QT Vascular Ltd (5I0.SI) | 220.08% |
| Simavita Ltd (SVA.AX) | 123.54% |
| Cochlear Ltd (COH.AX) | 19.39% |
Compared to its competitors, Imagion Biosystems Ltd's ROE (Return on Equity) is among the highest compared to peers, suggesting efficient use of shareholder equity to generate profits.